Lang Brian Hung-Hin, Poon Ronnie Tung-Ping, Fan Sheung-Tat, Wong John
Centre for the Study of Liver Disease and Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong.
Arch Surg. 2003 Nov;138(11):1207-13. doi: 10.1001/archsurg.138.11.1207.
Major hepatic resection is safe and provides favorable long-term survival for cirrhotic patients with a small solitary hepatocellular carcinoma.
Retrospective case series.
Tertiary referral center.
From January 1, 1989, to December 31, 2001, 218 cirrhotic patients with a solitary hepatocellular carcinoma 5 cm or less in diameter underwent either a major hepatic resection (n = 84) or a minor hepatic resection (n = 134).
Perioperative morbidity and mortality, and long-term survival rates.
The major resection group had significantly larger tumors (median, 3.5 vs 2.5 cm; P<.001) and better liver function (median indocyanine green retention at 15 minutes, 9.3% vs 12.9%; P<.001) than the minor resection group. Postoperative morbidity (46.4% vs 39.6%) and mortality (8.3% vs 3.0%) were higher in the major resection group than in the minor resection group, but the differences did not reach statistical significance (P =.32 and P =.11, respectively). The median overall survival did not differ significantly between the 2 groups (102.0 vs 72.3 months; P =.25). However, the median disease-free survival in the major resection group was significantly better than that in the minor resection group (59.0 vs 29.5 months; P =.03). On further subgroup analysis, both disease-free and overall survival rates were significantly better in the major hepatic resection group for tumors of 3 to 5 cm.
In well-selected cirrhotic patients with a small, solitary hepatocellular carcinoma, major hepatic resection is safe and may offer a better long-term survival over minor hepatic resection for patients with tumors of 3 to 5 cm.
对于患有小的孤立性肝细胞癌的肝硬化患者,进行大范围肝切除是安全的,并能提供良好的长期生存率。
回顾性病例系列研究。
三级转诊中心。
从1989年1月1日至2001年12月31日,218例直径5厘米及以下的孤立性肝细胞癌肝硬化患者接受了大范围肝切除(n = 84)或小范围肝切除(n = 134)。
围手术期发病率和死亡率,以及长期生存率。
与小范围肝切除组相比,大范围肝切除组的肿瘤明显更大(中位数,3.5厘米对2.5厘米;P <.001),肝功能更好(15分钟时吲哚菁绿滞留中位数,9.3%对12.9%;P <.001)。大范围肝切除组的术后发病率(46.4%对39.6%)和死亡率(8.3%对3.0%)高于小范围肝切除组,但差异未达到统计学意义(分别为P =.32和P =.11)。两组的总生存中位数无显著差异(102.0个月对72.3个月;P =.25)。然而,大范围肝切除组的无病生存中位数明显优于小范围肝切除组(59.0个月对29.5个月;P =.03)。进一步的亚组分析显示,对于3至5厘米的肿瘤,大范围肝切除组的无病生存率和总生存率均显著更好。
在精心挑选的患有小的孤立性肝细胞癌的肝硬化患者中,对于肿瘤大小为3至5厘米的患者,大范围肝切除是安全的,并且与小范围肝切除相比可能提供更好的长期生存。